MobiHealth News June 24, 2025
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Pharma giant Novo Nordisk announced that it is terminating its contract with direct-to-consumer virtual care company Hims & Hers, which was launched less than two months ago, due to concerns about Hims & Hers’ “illegal mass compounding and deceptive marketing.”
In late April, the FDA announced that the national shortage of the GLP-1 weight-loss drug Wegovy had been resolved, stating that Novo Nordisk was able to meet the projected demand.
Following the announcement, the pharma giant began partnering with telehealth companies to offer Wegovy through NovoCare Pharmacy, its platform that allows...
Today's Sponsors
Today's Sponsor